Needs: This course addresses the need to understand how to increase reliability in the diagnosis and follow-up of monocytic leukemias. The specific clinical gap to be addressed by pathologists has been demonstrated in a recent multicenter study “concordance among hematopathologists in classifying blasts plus promonocytes: a bone marrow pathology study.” Recent studies in the biology of our newly discovered biomarker raises the possibility that it may be involved in tumor susceptibility to new therapies.

Objectives: Understand the diagnostic and clinical dilemma surrounding myeloid neoplasms with monocytic differentiation; Appreciate the advantages and limitations of a new biomarker to be used on core bone marrow biopsies and soft tissue samples; Learn about the biology of IRF8 in the context of hematopoietic neoplasms.